Atlas Trials

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Clinical trial NCT04795245 · COMPLETED

Trial details

NCT number
NCT04795245
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Study type
OBSERVATIONAL
Non-squamous, Non-Small Cell Lung Cancer
Start date
2021-08-26
Primary completion
2023-10-16
Enrollment
805

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.